title: The hexamer structure of Rift Valley fever virus nucleoprotein suggests a mechanism for its assembly into ribonucleoprotein complexes.
abstract: Rift Valley fever virus (RVFV), a Phlebovirus with a genome consisting of three single-stranded RNA segments, is spread by infected mosquitoes and causes large viral outbreaks in Africa. RVFV encodes a nucleoprotein (N) that encapsidates the viral RNA. The N protein is the major component of the ribonucleoprotein complex and is also required for genomic RNA replication and transcription by the viral polymerase. Here we present the 1.6 Å crystal structure of the RVFV N protein in hexameric form. The ring-shaped hexamers form a functional RNA binding site, as assessed by mutagenesis experiments. Electron microscopy (EM) demonstrates that N in complex with RNA also forms rings in solution, and a single-particle EM reconstruction of a hexameric N-RNA complex is consistent with the crystallographic N hexamers. The ring-like organization of the hexamers in the crystal is stabilized by circular interactions of the N terminus of RVFV N, which forms an extended arm that binds to a hydrophobic pocket in the core domain of an adjacent subunit. The conformation of the N-terminal arm differs from that seen in a previous crystal structure of RVFV, in which it was bound to the hydrophobic pocket in its own core domain. The switch from an intra- to an inter-molecular interaction mode of the N-terminal arm may be a general principle that underlies multimerization and RNA encapsidation by N proteins from Bunyaviridae. Furthermore, slight structural adjustments of the N-terminal arm would allow RVFV N to form smaller or larger ring-shaped oligomers and potentially even a multimer with a super-helical subunit arrangement. Thus, the interaction mode between subunits seen in the crystal structure would allow the formation of filamentous ribonucleocapsids in vivo. Both the RNA binding cleft and the multimerization site of the N protein are promising targets for the development of antiviral drugs.
authors: Architecture et Fonction des Macromolécules Biologiques, Marseille, France.
authors: François
authors: F
authors: Ferron
authors: Zongli
authors: Z
authors: Li
authors: Eric I
authors: EI
authors: Danek
authors: Dahai
authors: D
authors: Luo
authors: Yeehwa
authors: Y
authors: Wong
authors: Bruno
authors: B
authors: Coutard
authors: Violaine
authors: V
authors: Lantez
authors: Rémi
authors: R
authors: Charrel
authors: Bruno
authors: B
authors: Canard
authors: Thomas
authors: T
authors: Walz
authors: Julien
authors: J
authors: Lescar
references: J Virol. 1977 Mar;21(3):1085-93
references: 850304
references: J Virol. 2002 Nov;76(21):10849-60
references: 12368328
references: C R Acad Hebd Seances Acad Sci D. 1975 Feb 10;280(6):779-82
references: 808354
references: J Virol. 2009 Oct;83(20):10719-36
references: 19640978
references: Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
references: 20124692
references: Science. 2006 Jul 21;313(5785):357-60
references: 16778022
references: J Virol. 2009 Nov;83(21):11402-6
references: 19692473
references: J Virol. 2000 Nov;74(21):9946-52
references: 11024122
references: J Virol. 1995 Jul;69(7):3972-9
references: 7769655
references: J Comput Chem. 2004 Oct;25(13):1605-12
references: 15264254
references: J Mol Biol. 2004 Jul 2;340(2):319-31
references: 15201055
references: Science. 2009 Nov 27;326(5957):1279-83
references: 19965480
references: J Mol Biol. 2004 May 28;339(2):301-12
references: 15136034
references: Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11769-74
references: 20547879
references: Acta Crystallogr D Biol Crystallogr. 2001 Jan;57(Pt 1):122-33
references: 11134934
references: Antiviral Res. 2010 Feb;85(2):328-45
references: 19857523
references: J Gen Virol. 1971 Nov;13(2):335-7
references: 5168243
references: Acta Crystallogr D Biol Crystallogr. 2001 Oct;57(Pt 10):1445-50
references: 11567158
references: Acta Crystallogr D Biol Crystallogr. 1996 Jul 1;52(Pt 4):842-57
references: 15299650
references: J Virol. 1975 Feb;15(2):386-92
references: 1167604
references: C R Acad Hebd Seances Acad Sci D. 1976 May 3;282(17):1653-5
references: 820471
references: J Microsc. 1987 May;146(Pt 2):113-36
references: 3302267
references: Biol Proced Online. 2004;6:23-34
references: 15103397
references: Vaccine. 2009 Nov 5;27 Suppl 4:D69-72
references: 19837291
references: Euro Surveill. 2010 Mar 11;15(10):19506
references: 20403309
references: Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
references: 15572765
references: J Virol. 2005 Sep;79(18):11974-80
references: 16140773
references: J Struct Biol. 1996 Jan-Feb;116(1):190-9
references: 8742743
references: J Mol Biol. 2006 Feb 3;355(5):1048-65
references: 16343539
references: J Gen Virol. 1995 Apr;76 ( Pt 4):1009-14
references: 9049350
references: PLoS Pathog. 2010 Sep 16;6(9):e1001038
references: 20862324
references: J Gen Virol. 1998 Dec;79 ( Pt 12):2909-19
references: 9880004
references: Int J Antimicrob Agents. 2003 Feb;21(2):153-7
references: 12615379
references: Science. 2006 Jul 21;313(5785):360-3
references: 16778023
references: Virol J. 2007 Jul 10;4:72
references: 17623082
references: J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
references: 19461840
references: Nucleic Acids Res. 2003 Jul 1;31(13):3320-3
references: 12824317
references: Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22
references: 18156677
references: Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):955-9
references: 19144928
references: J Virol. 2005 Mar;79(6):3586-94
references: 15731253
references: Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
references: 15034147
references: Mol Biol Evol. 2010 Feb;27(2):221-4
references: 19854763
references: Virol J. 2008 Jul 18;5:82
references: 18638365